Literature DB >> 6811419

Humoral immune response and expression of spontaneous postnatal amelanosis in DAM line chickens.

S J Lamont, R E Boissy, J R Smyth.   

Abstract

The delayed amelanotic (DAM) chicken line has been developed as a model of human vitiligo. Vitiligo in humans and chickens is characterized symptomatically by spontaneous loss of integumentary pigmentation and is often associated with uveitis. In humans, vitiligo is also associated with increased frequencies of several autoantibodies, suggesting a state of immune hyperreactivity. An adult DAM chicken population was tested for levels of circulating antibody after challenge with sheep red blood cells or Brucella abortus. There was a significantly higher mean titer level to both antigens in the amelanotic birds than in normally pigmented birds. The severity of feather amelanosis and visual defects was associated with increased antibody levels. This suggests that amelanosis and blindness in DAM chickens may be associated with elevated antibody responses to foreign antigens and perhaps with a generalized state of hyperimmunity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6811419     DOI: 10.3109/08820138209057748

Source DB:  PubMed          Journal:  Immunol Commun        ISSN: 0090-0877


  3 in total

1.  Analysis of the effect of endogenous viral genes in the Smyth line chicken model for autoimmune vitiligo.

Authors:  G P Sreekumar; J R Smyth; S Ambady; F A Ponce de Leon
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Persistence of abnormal melanocytes in immunosuppressed chickens of the autoimmune "DAM" line.

Authors:  R E Boissy; S J Lamont; J R Smyth
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

3.  Progressive cytologic changes during the development of delayed feather amelanosis and associated choroidal defects in the DAM chicken line. A vitiligo model.

Authors:  R E Boissy; J R Smyth; K V Fite
Journal:  Am J Pathol       Date:  1983-05       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.